Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 18, 2019 07:00 ET | Source: Agios Pharmaceuticals, Inc.

Agios to Webcast Conference Call of Second Quarter 2019 Financial Results on August 1, 2019

CAMBRIDGE, Mass., July 18, 2019 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today...
July 01, 2019 07:00 ET | Source: Agios Pharmaceuticals, Inc.

Agios Announces Orlando Oliveira Appointed as Senior Vice President and General Manager, International

CAMBRIDGE, Mass., July 01, 2019 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced...
June 10, 2019 13:12 ET | Source: Agios Pharmaceuticals, Inc.

Agios to Present at the Goldman Sachs Global Healthcare Conference on Tuesday, June 11, 2019

CAMBRIDGE, Mass., June 10, 2019 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced...
June 05, 2019 16:00 ET | Source: Agios Pharmaceuticals, Inc.

Agios Announces the Planned Retirement of Chief Scientific Officer, Scott Biller, Ph.D., Effective December 31, 2019

– Search Initiated for Company’s Next Chief Scientific Officer – – Dr. Biller to Remain a Strategic Advisor to Agios Through 2020 – CAMBRIDGE, Mass., June 05, 2019 (GLOBE NEWSWIRE) -- Agios...
June 03, 2019 08:00 ET | Source: Agios Pharmaceuticals, Inc.

Agios Presents Updated Data from Phase 1 Studies of TIBSOVO® (ivosidenib) in Newly Diagnosed Adult Patients with IDH1 Mutant Acute Myeloid Leukemia (AML) Not Eligible for Intensive Chemotherapy

– With Longer Follow Up, CR+CRh Rate Increased to 70% and CR Rate Increased to 61% in the Phase 1 Study of TIBSOVO® in Combination with Azacitidine – – Phase 1 Data of Single Agent TIBSOVO®...
May 15, 2019 16:05 ET | Source: Agios Pharmaceuticals, Inc.

Agios to Present Clinical Data from its IDH Program at ASCO

CAMBRIDGE, Mass., May 15, 2019 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced...
May 15, 2019 16:01 ET | Source: Agios Pharmaceuticals, Inc.

Agios Announces the Randomized Phase 3 ClarIDHy Trial of TIBSOVO® (ivosidenib) Achieved its Primary Endpoint in Previously Treated IDH1 Mutant Cholangiocarcinoma Patients

– TIBSOVO® Demonstrated a Statistically Significant Improvement in Progression-Free Survival Compared to Placebo – – Safety Profile Consistent with Published Phase 1 Data in Patients with IDH1 Mutant...
May 02, 2019 13:18 ET | Source: Agios Pharmaceuticals, Inc.

Agios Announces FDA Approval of Supplemental New Drug Application (sNDA) for TIBSOVO® as Monotherapy for Newly Diagnosed Adult Patients with IDH1 Mutant Acute Myeloid Leukemia (AML) Not Eligible for Intensive Chemotherapy

– TIBSOVO® is the First and Only Therapy Approved for Newly Diagnosed AML Patients with an IDH1 Mutation who are Ineligible for Intensive Chemotherapy – – sNDA Approval Based on 28 Newly Diagnosed...
May 02, 2019 07:00 ET | Source: Agios Pharmaceuticals, Inc.

Agios Reports Business Highlights and First Quarter 2019 Financial Results

– Commercial Organization Launch Ready Ahead of June 21, 2019 PDUFA Action Date for Single Agent TIBSOVO® for IDH1m Newly Diagnosed AML – – Updated Data from Phase 1 Studies of TIBSOVO® in Newly...
April 25, 2019 16:00 ET | Source: Agios Pharmaceuticals, Inc.

Agios to Webcast Conference Call of First Quarter 2019 Financial Results on May 2, 2019

CAMBRIDGE, Mass., April 25, 2019 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today...